Montefiore St. Luke’s Cornwall is First Hospital in NYS to Offer the HYDROS™ Robotic System, the Next-Generation AI-Powered Platform for Aquablation® Therapy to Treat BPH
Newburgh, NY [October 30, 2024] – Montefiore St Luke’s Cornwall is the first hospital in New York State to offer Aquablation® therapy with the new HYDROS™ Robotic System, the next-generation platform to treat men suffering from benign prostatic hyperplasia (BPH), commonly known as an enlarged prostate. Aquablation therapy, now delivered by an AI-powered robotic system, is clinically proven to provide significant, durable BPH symptom relief while preserving sexual function and continence across prostates of all shapes and sizes.
“Advancements in surgical technology, like Aquablation® therapy, are transforming the way we approach patient care,” said Daniel Maughan, MSLC President and CEO. With innovative equipment, it enhances greater precision, reduces recovery times, and improves overall outcomes for our patients. We are so proud to be the first hospital in New York State to offer this advanced treatment.”
BPH is a reality of aging for millions of men and impacts urinary function, making it difficult to urinate and fully empty the bladder. Common indicators that a man may be experiencing BPH are the need to urinate immediately or urgently, urinating more often than normal and urinating frequently at night. Without timely treatment, BPH can lead to severe health issues such as permanent bladder or kidney damage, bladder stones and incontinence. One in two men ages 51-60 have BPH1 and 99 percent of men say BPH impacts their quality of life2.
“BPH is a widespread condition that severely compromises quality of life for countless men over age 50. With Aquablation therapy, men can reclaim their lifestyles and find relief from symptoms while preserving sexual function and continence; outcomes that have proven elusive with many traditional treatment modalities,” said Dr. Jaspreet Singh, Medical Staff President and Urologist at MSLC.
To learn more about this procedure at Montefiore St. Luke’s Cornwall, please call (845) 240- 2742 or email today. Additional information is also on the MSLC Website, linked here.
Aquablation therapy is designed to offer a minimally invasive and effective solution for BPH, minimizing the need for men to choose between safety and efficacy. Aquablation therapy is unique in its use of real-time, ultrasound-guided, robotic-assisted waterjet technology, allowing surgeons to create a personalized treatment plan that precisely targets which prostate tissue to remove and which to preserve. With this tailored approach, the system accurately removes problematic tissue while safeguarding critical anatomy.
The HYDROS Robotic System represents the next evolution in the delivery of Aquablation therapy. Leveraging insights from over 50,000 procedures, HYDROS features FirstAssist AI™ treatment planning, advanced image guidance, robotic resection, and a streamlined workflow. HYDROS is designed to improve efficiency, enhance surgeon and staff experience, and deliver a more accurate and consistent treatment plan for better clinical outcomes.
The clinically proven procedure integrates next-generation ultrasound imaging and digital cystoscopy to provide the surgeon with a multi-dimensional, detailed view of the entire prostate, enabling personalized treatment planning tailored to each patient’s unique anatomy. Utilizing a heat-free waterjet, the robot executes the surgeon-defined treatment plan to remove obstructive tissue while protecting critical anatomy. This enables efficient and predictable waterjet resection, standardizing the operative experience across a wide range of prostate sizes and shapes.
Aquablation therapy is backed by 5-year clinical data demonstrating significant durable symptom relief while preserving sexual function and continence across prostates of all shapes and sizes.
For more information on Aquablation therapy, visit aquablation.com.
About Montefiore St. Luke’s Cornwall
Montefiore St. Luke’s Cornwall (MSLC) is one of nine hospitals within the Montefiore Health System (MHS). MSLC is dedicated to serving the healthcare needs of the Hudson Valley. Through its system relationship with MHS MSLC provides the necessary tertiary and quaternary care to best care for more than 250,000 patients annually. For more information, please visit www.montefioreslc.org.
